Chonluten T-34 (20mg)

Chonluten (T-34, 20mg): Glu-Asp-Gly (EDG) Tripeptide — A Khavinson Bronchopulmonary-Specific Short Peptide Bioregulator (Cytogen) with the Amino Acid Sequence Glutamic Acid-Aspartic Acid-Glycine (EDG), Developed by Professor Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology, Proposed to Penetrate the Cell Membranes and Nuclear Membranes of Bronchial and Alveolar Epithelial Cells, Bind Directly to Specific DNA Regulatory Regions in Gene Promoters, Modulate Gene Expression Involved in Tissue Regeneration and Immune Homeostasis in the Respiratory System, Stimulate Proliferation and Differentiation of Bronchial Mucosal Epithelial Cells, Restore Ciliary Function and Mucociliary Clearance, Support Surfactant Production by Type II Pneumocytes, Exert Anti-Inflammatory Effects (via COX-2 Regulation, TNF-α Suppression in LPS-Stimulated Monocytes, Reduction of IL-6 and IL-1β), Upregulate Antioxidant Enzymes (Superoxide Dismutase [SOD] and Catalase), Modulate DNA Methylation (Activating STAT1 for Healthy Immune Signaling While Downregulating STAT3 Associated with Aggressive Inflammation), and Normalize Cytokine Profiles in Lung Tissue — With Preclinical and Clinical Observations from Russian Research Groups Suggesting Potential Benefits in Chronic Obstructive Pulmonary Disease (COPD), Chronic Bronchitis (Including Smokers and Occupationally Exposed Workers), Post-Tuberculosis Rehabilitation, and Age-Related Pulmonary Involution (Senile Pulmonary Involution), But With Important Limitations Including No Independent Western Validation, No Large-Scale Randomized Controlled Trials, Literature That Is Sparse, Old, and Predominantly Russian-Language, and Notably a Negative Finding in Khavinson's Own Research Where the T-34 Peptide of the Respiratory System Was Reported as Ineffective in One Geroprotective Study

Chonluten — also known by the research code T-34 and as the EDG tripeptide (referring to its amino acid sequence Glutamic acid-Aspartic acid-Glycine, using single-letter amino acid codes: E = glutamic acid, D = aspartic acid, G = glycine) — is a synthetic tripeptide bioregulator developed by Professor Vladimir Khavinson and his research group at the Saint Petersburg Institute of Bioregulation and Gerontology in Russia, as part of their systematic research program identifying organ-specific ultrashort peptides (typically 2-4 amino acids) proposed to act as tissue-specific "information molecules" that regulate gene expression and cellular function. Chonluten is the bronchopulmonary-specific member of the Khavinson peptide family, designed to target the respiratory system — specifically the lungs, bronchial tree, bronchial epithelium, and alveolar epithelium — supporting respiratory epithelial function, mucociliary clearance, surfactant production, and immune homeostasis in lung tissue. It is classified as a Cytogen — a laboratory-synthesized short peptide bioregulator designed to mirror the regulatory effects of peptides naturally found in bronchial and lung tissue. With a molecular weight of approximately 289 Daltons (for the free tripeptide Glu-Asp-Gly), Chonluten is among the smallest bioregulator peptides in the Khavinson series — a property that facilitates rapid systemic distribution, cellular uptake, and penetration into the nucleus (where it is proposed to interact with DNA). Unlike most conventional drugs and many research peptides that work through binding to specific cell-surface receptors (G protein-coupled receptors, receptor tyrosine kinases, cytokine receptors, etc.) and triggering intracellular signaling cascades, Chonluten is proposed to work through a fundamentally different mechanism: direct epigenetic and gene-regulatory action at the level of chromatin and DNA, penetrating the cell membranes and nuclear membranes of bronchial and alveolar epithelial cells, entering the nucleus, binding directly to specific DNA regulatory regions in gene promoters, and modulating the expression of genes involved in tissue regeneration, cellular differentiation, antioxidant defense, inflammation regulation, and immune homeostasis in the respiratory system. It is important to note from the outset that the evidence base for Chonluten is significantly limited: all published research originates from Russian institutes (primarily Khavinson's group and collaborators at Saint Petersburg pulmonology centers), there is no independent Western validation, the literature is sparse, relatively old, and predominantly Russian-language, there are no large-scale randomized controlled trials (RCTs), and — notably — there is even a negative finding in Khavinson's own research, where the T-34 peptide of the respiratory system was reported as ineffective in one geroprotective study (Khavinson, "Morphofunctional Fundamentals for Peptide Regulation of Aging"). This negative finding must be kept in mind when evaluating claims about Chonluten's efficacy, and it underscores the experimental and investigational nature of this peptide. Chonluten is NOT FDA-approved for any indication in the United States, is not approved as a prescription medication in most Western countries, and is classified as a research chemical/investigational peptide^{[1][2][3][4][5][6][7][8][9][10][11][12]}.

Mechanism of Action: Nuclear Penetration, DNA Promoter Binding, Bronchopulmonary Gene Regulation, and Respiratory Epithelial Homeostasis

The proposed mechanism of action of Chonluten — like other Khavinson peptide bioregulators — is fundamentally epigenetic and gene-regulatory, rather than receptor-mediated or enzymatic. Chonluten is proposed to act directly at the level of chromatin structure and gene expression in bronchial and alveolar epithelial cells, rather than through binding to cell-surface receptors and triggering conventional signaling cascades. The proposed mechanism involves the following key steps and downstream effects, illustrated in the mechanism diagram below^{[1][2][3][4][5][6][7][8]}:

The key mechanistic steps and downstream effects can be summarized as follows^{[1][2][3][4][5][6][7][8]}:

1. Cellular and nuclear penetration: After administration (typically by subcutaneous or intramuscular injection, though oral formulations have also been studied in Russian clinical protocols), Chonluten — being a very small tripeptide (~289 Da) — is rapidly absorbed and distributed systemically. Unlike larger peptides and proteins that may have difficulty crossing cell membranes, short peptides like Chonluten are proposed to enter cells through passive diffusion (facilitated by their small size) and possibly through peptide transporter systems. Once inside the cell, the tripeptide is small enough to passively diffuse through nuclear pore complexes (which allow passage of molecules smaller than ~40-60 kDa, so a 289 Da peptide easily passes) to enter the nucleus, where it can interact with nuclear and chromatin structures — specifically, DNA in gene promoter regions and histone proteins. This ability to penetrate both cell and nuclear membranes is a foundational premise of the Khavinson peptide bioregulator theory, and Chonluten's small molecular size makes this mechanistically plausible.
2. DNA promoter binding and chromatin remodeling: The central mechanistic step is the proposed complementary binding of Chonluten (EDG) to specific DNA sequences in the promoter regions of bronchopulmonary-specific genes, and to histone proteins, leading to chromatin remodeling — specifically, the decondensation of heterochromatin (the tightly packed, transcriptionally silent form of chromatin) and the restoration of transcriptional access to age-silenced or disease-silenced respiratory genes. According to the Khavinson theory, short peptides bind complementarily to specific DNA sequences in gene promoter regions — with the peptide's amino acid sequence determining which DNA sequences it recognizes and binds to, through complementary charge interactions and hydrogen bonding between the peptide's amino acid side chains and the DNA's nucleotide bases. For Chonluten (EDG), the proposed target genes include stress-response genes (c-Fos, heat shock protein 70 [HSP70]), antioxidant enzymes (superoxide dismutase [SOD], catalase), inflammatory mediators (cyclooxygenase-2 [COX-2], tumor necrosis factor-alpha [TNF-α]), and differentiation/proliferation markers in bronchial epithelium. Chonluten also binds to histone proteins, modifying their post-translational modification state — including regulation of DNA methylation (activating STAT1 to support healthy immune signaling while dialing down STAT3, which is linked to aggressive inflammation). The net effect of these DNA and histone interactions is the decondensation of heterochromatin — converting the tightly packed, transcriptionally silent DNA back into open, accessible, transcriptionally active euchromatin — which restores transcriptional access to bronchopulmonary-specific genes, allowing them to be re-expressed. It is important to note that, unlike the related Bronchogen (AEDL) tetrapeptide — for which biophysical studies using spectrophotometry, viscometry, and circular dichroism have demonstrated that the AEDL peptide interacts with DNA in the major groove at the guanine N7 site without visible distortion of the double helix structure, and binds specifically to a CTCC DNA sequence motif — the specific DNA binding sequences, binding affinities, and genome-wide binding patterns of Chonluten (EDG) have NOT been characterized by high-resolution structural biology techniques (X-ray crystallography, cryo-EM, NMR, ChIP-seq, EMSA, SPR, ITC). This means that Chonluten's DNA-binding mechanism remains a working hypothesis with significant mechanistic uncertainty, and the pharmacological challenges (how a 3-amino-acid peptide achieves sufficient DNA sequence specificity for bronchopulmonary tissue selectivity, actual binding affinity unmeasured, in vivo bioavailability and lung tissue penetration not fully characterized, plasma stability with potential aminopeptidase degradation of the N-terminal glutamic acid) have not been fully resolved.
3. Bronchial epithelial proliferation, differentiation, and mucociliary clearance restoration: As a consequence of chromatin decondensation and gene reactivation, Chonluten is proposed to stimulate the proliferation and differentiation of bronchial mucosal epithelial cells — the cells that line the bronchial tree and are responsible for maintaining the epithelial barrier, producing mucus, and bearing the cilia that drive mucociliary clearance (the primary innate defense mechanism of the respiratory tract, which clears inhaled particles, pathogens, and excess mucus from the lungs). Chonluten is proposed to restore ciliary function and ciliated cell-associated structural gene expression, and to modulate mucin gene expression — particularly MUC5AC, the major gel-forming mucin in the respiratory tract that is responsible for the viscoelastic properties of mucus and is dysregulated in chronic bronchitis, COPD, and asthma (where excessive MUC5AC production leads to mucus hypersecretion and plugging). By restoring ciliary function and regulating mucin production, Chonluten is proposed to enhance mucociliary clearance — the coordinated action of ciliary beating and mucus production that clears the respiratory tract — which is impaired in virtually all chronic respiratory diseases (COPD, chronic bronchitis, bronchiectasis, cystic fibrosis, asthma) and is a major contributor to recurrent infections, airflow obstruction, and disease progression.
4. Surfactant production support by type II pneumocytes: In addition to its effects on bronchial epithelium, Chonluten is proposed to support surfactant production by type II pneumocytes (also called type II alveolar epithelial cells or great alveolar cells) — the specialized cells in the alveoli (the tiny air sacs where gas exchange occurs) that produce pulmonary surfactant, a complex mixture of phospholipids (primarily dipalmitoylphosphatidylcholine [DPPC]) and surfactant proteins (SP-A, SP-B, SP-C, SP-D) that reduces surface tension at the air-liquid interface in the alveoli, preventing alveolar collapse (atelectasis) during exhalation and reducing the work of breathing. Surfactant dysfunction or deficiency is a key feature of acute respiratory distress syndrome (ARDS), neonatal respiratory distress syndrome (NRDS), and is also impaired in COPD, pneumonia, and lung injury. Chonluten is proposed to upregulate surfactant protein gene expression in type II pneumocytes, supporting adequate surfactant production and maintaining alveolar stability. Some Khavinson publications have reported increased expression of surfactant protein genes with Chonluten treatment, and have proposed Chonluten as a candidate for investigation of lung tissue regeneration — though no in vivo data were presented in that specific publication.
5. Anti-inflammatory effects (COX-2, TNF-α, IL-6, IL-1β, STAT1/STAT3): Chonluten is proposed to exert significant anti-inflammatory effects in lung tissue, through multiple complementary mechanisms: (a) COX-2 regulation — Chonluten regulates the expression of cyclooxygenase-2 (COX-2), the inducible enzyme responsible for prostaglandin synthesis during inflammation (prostaglandins are key mediators of inflammation, pain, and fever, and COX-2 is the target of NSAIDs like celecoxib); by regulating COX-2 expression, Chonluten may reduce excessive prostaglandin-mediated inflammation in the respiratory tract; (b) TNF-α suppression — in the THP-1 monocyte/macrophage cell line (a widely used model of human monocyte/macrophage function), Chonluten inhibited tumor necrosis factor (TNF) production by monocytes exposed to bacterial lipopolysaccharide (LPS) — a model of acute inflammatory stimulation; this finding was reported in a 2022 publication in the International Journal of Molecular Sciences (with Khavinson as co-author), in which Chonluten — among several Khavinson peptides — reduced LPS-stimulated TNF and IL-6 in human THP-1 monocytes/macrophages and altered proliferation/apoptosis and extracellular vesicle production; (c) IL-6 and IL-1β reduction — reductions in IL-6 (a pro-inflammatory cytokine tied to chronic inflammation) and IL-1β expression have been described in stressed mucosal-epithelium cultures exposed to EDG; (d) STAT1 activation / STAT3 downregulation — Chonluten regulates DNA methylation, flipping the switches that determine which genes get turned on or off — specifically, activating STAT1 to support healthy immune signaling while dialing down STAT3, which is linked to aggressive inflammation; and (e) cytokine profile normalization — Chonluten exhibits immunomodulatory properties by normalizing cytokine profiles in lung tissue and reducing pathological inflammatory signaling. These anti-inflammatory effects are particularly relevant for chronic respiratory diseases like COPD and chronic bronchitis, where chronic inflammation (driven by TNF-α, IL-6, IL-1β, and other cytokines) is a central pathogenic mechanism that drives airway remodeling, mucus hypersecretion, alveolar destruction (emphysema), and progressive airflow limitation.
6. Antioxidant defense upregulation (SOD, catalase) and age-related decline reversal: Chonluten is proposed to upregulate antioxidant defense enzymes — specifically superoxide dismutase (SOD) and catalase — in respiratory epithelial cells. SOD is the enzyme that catalyzes the dismutation of superoxide radicals (O2•−) into oxygen and hydrogen peroxide (H2O2), and catalase is the enzyme that breaks down hydrogen peroxide into water and oxygen — together, these enzymes form the primary enzymatic defense against reactive oxygen species (ROS) and oxidative stress. Oxidative stress — driven by an imbalance between ROS production and antioxidant defense — is a key contributor to lung damage in COPD (particularly in smokers, where cigarette smoke generates enormous amounts of ROS), asthma, acute lung injury, and aging lungs (where age-associated declines in antioxidant enzyme activity contribute to "senile pulmonary involution" or age-related lung function decline). By upregulating SOD and catalase, Chonluten is proposed to enhance antioxidant defense in lung tissue, reducing oxidative damage to respiratory epithelial cells, lipids, proteins, and DNA. Gerontological studies in aged rodents have documented age-associated declines in bronchial ciliated cell density, mucociliary clearance, and antioxidant enzyme activity that are partially reversed by cyclic Chonluten administration, supporting the bioregulator hypothesis underpinning Khavinson's work — though these findings are limited to rodent models and have not been validated in humans.

Preclinical and Clinical Evidence, Proposed Indications, and Important Limitations (Including a Negative Finding)

The evidence base for Chonluten is significantly more limited than for many other research peptides, and it is important to be transparent about these limitations — including a notable negative finding in Khavinson's own research. The entire published record on Chonluten consists of preclinical studies (in vitro tissue culture experiments and limited animal models) and clinical observations from Russian research groups (primarily at Saint Petersburg pulmonology centers), with no independent Western validation, no large-scale randomized controlled trials (RCTs), literature that is sparse, relatively old, and predominantly Russian-language, and — as noted — even a negative finding in Khavinson's own research. Independent evidence reviewers (such as PepHealth in Brazil) have summarized the evidence status bluntly: Chonluten (sometimes confused with Bronchogen) is a short peptide from the Russian Khavinson school, proposed as a "bioregulator" of the bronchi; it is NOT approved (no ANVISA/FDA/EMA), has no robust RCT, and its mechanism in humans is not established; the literature is scarce, old, and mostly Russian. With that important context, the available preclinical and clinical findings include^{[1][2][3][4][5][6][7][8][9][10][11][12]}:

Chronic Obstructive Pulmonary Disease (COPD): COPD is the primary proposed indication for Chonluten, given its bronchopulmonary specificity and proposed effects on mucociliary clearance, inflammation, and oxidative stress. Animal models of COPD report that Chonluten administration reduces inflammatory infiltrate (the accumulation of inflammatory cells like neutrophils and macrophages in the airways and lung parenchyma), normalizes alveolar architecture (reducing the alveolar destruction and enlargement characteristic of emphysema), and improves indices of respiratory mechanics relative to untreated controls — supporting its inclusion in Russian-language respiratory rehabilitation protocols. In clinical settings, oral administration of Chonluten (EDG) combined with Bronchogen (AEDL) has been reported effective for treatment of bronchopulmonary pathology including COPD and chronic bronchitis with asthmatic component. The EDG tripeptide reportedly enhanced the effectiveness of standard therapy in patients with chronic bronchitis. However, these clinical observations are from Russian studies and have NOT been validated through randomized, controlled trials — so they should be considered preliminary and hypothesis-generating, not definitive evidence of efficacy.

Chronic bronchitis (smokers and occupationally exposed workers): Chronic bronchitis — defined clinically as a chronic productive cough for at least three months in each of two consecutive years — is most commonly caused by cigarette smoking, but also affects workers with occupational exposures to dust, fumes, and irritants (such as coal miners, construction workers, agricultural workers, and industrial workers). Clinical series from Saint Petersburg pulmonology centers have described reductions in cough frequency, sputum volume, and exacerbation rate when Chonluten courses are added to standard care in patients with chronic bronchitis — including smokers and occupationally exposed workers. These findings are consistent with Chonluten's proposed mechanisms (restored mucociliary clearance, reduced mucus hypersecretion via MUC5AC regulation, anti-inflammatory effects, enhanced antioxidant defense against cigarette smoke-induced oxidative stress). However, as with the COPD data, these are clinical observations from Russian centers without RCT validation, and the magnitude and durability of effects are not well-characterized.

Post-tuberculosis rehabilitation: In the Russian TB clinical tradition — which has a long history of using peptide bioregulators in tuberculosis treatment and rehabilitation — Chonluten has been studied as part of multi-peptide protocols during the recovery phase after tuberculosis treatment, with reported improvements in spirometry (lung function tests including FEV1, FVC, and FEV1/FVC ratio) and exercise tolerance. Tuberculosis (particularly pulmonary TB) causes significant lung damage — including cavitation, fibrosis, bronchiectasis, and impaired mucociliary clearance — that persists even after successful antimicrobial treatment, and post-TB rehabilitation is an important but often neglected aspect of TB care. Chonluten's proposed effects on bronchial epithelial repair, mucociliary clearance, surfactant production, and inflammation normalization make it a theoretically interesting candidate for post-TB lung rehabilitation. However, the evidence is limited to Russian clinical observations without RCT validation, and Chonluten should NOT be considered a replacement for standard antimicrobial TB treatment or evidence-based pulmonary rehabilitation.

Senile pulmonary involution (age-related lung function decline): "Senile pulmonary involution" refers to the age-related decline in lung function and structural integrity that occurs with aging — including reductions in lung elasticity, alveolar surface area, ciliary function, mucociliary clearance, antioxidant enzyme activity, and immune defense, leading to increased susceptibility to respiratory infections, reduced exercise tolerance, and increased risk of chronic respiratory disease. Gerontological studies in aged rodents have documented that age-associated declines in bronchial ciliated cell density, mucociliary clearance, and antioxidant enzyme activity are partially reversed by cyclic Chonluten administration — supporting the bioregulator hypothesis underpinning Khavinson's work (that short peptides can reverse age-related cellular dysregulation by restoring youthful gene expression patterns). These findings are consistent with Chonluten's proposed mechanisms (epithelial proliferation/differentiation, ciliary function restoration, antioxidant enzyme upregulation). However, these findings are limited to rodent models and have not been validated in humans — and, importantly, Khavinson's own research in "Morphofunctional Fundamentals for Peptide Regulation of Aging" reported that "the T–34 peptide of the respiratory system was ineffective" in one geroprotective study — a negative finding that must be kept in mind and that suggests Chonluten's geroprotective effects may be context-dependent, assay-dependent, or less robust than for other Khavinson peptides (such as Thymalin and Epithalon, which have more extensive and consistent geroprotective data).

In vitro anti-inflammatory and immunomodulatory studies: The most mechanistically detailed in vitro data come from studies of Chonluten's effects on immune cells and epithelial cells: (a) a 2022 publication in the International Journal of Molecular Sciences (with Khavinson as co-author) reported that Chonluten — among several Khavinson peptides — reduced TNF and IL-6 stimulated by LPS in human THP-1 monocytes/macrophages, and altered proliferation/apoptosis and extracellular vesicle production; (b) COX-2 regulation studies have shown that Chonluten regulates the expression of cyclooxygenase-2, the inducible enzyme responsible for prostaglandin synthesis during inflammation; (c) TNF-α suppression studies in the THP-1 monocyte/macrophage cell line have shown that Chonluten inhibits TNF production by monocytes exposed to bacterial LPS; (d) IL-6 and IL-1β reduction studies in stressed mucosal-epithelium cultures exposed to EDG have shown reduced expression of these pro-inflammatory cytokines; and (e) antioxidant enzyme upregulation studies have shown increased SOD and catalase expression in respiratory epithelial cells. While these in vitro findings are consistent with the proposed anti-inflammatory and antioxidant mechanisms, it is critical to note that in vitro findings do not necessarily predict in vivo efficacy — cells in culture are removed from their normal three-dimensional tissue environment, mechanical conditions, systemic hormonal/inflammatory context, and pharmacokinetic constraints — and many compounds that show promising effects in vitro fail to demonstrate efficacy in animal models or human trials.

Important limitations, negative findings, and caveats: Several critical limitations must be emphasized when evaluating Chonluten: (1) no independent Western validation — all published research originates from Russian institutes, primarily Khavinson's group and Saint Petersburg pulmonology centers, with no independent replication by Western research groups; (2) no large-scale RCTs — there are no large-scale, randomized, double-blind, placebo-controlled human trials of Chonluten for any indication, so its safety, tolerability, pharmacokinetics, optimal dosing, and efficacy in humans are not established; (3) sparse, old, Russian-language literature — the published literature is limited in quantity, relatively old, and predominantly in Russian, making it difficult for the international scientific community to access, evaluate, and replicate; (4) negative finding in Khavinson's own research — notably, Khavinson's own publication "Morphofunctional Fundamentals for Peptide Regulation of Aging" reported that "the T–34 peptide of the respiratory system was ineffective" in one geroprotective study — this is a significant negative finding that must be disclosed and that suggests Chonluten's effects may be less consistent or robust than for other Khavinson peptides; (5) mechanism not fully confirmed by structural biology — unlike the related Bronchogen (AEDL) tetrapeptide (for which biophysical studies have demonstrated DNA major groove binding at guanine N7 and CTCC sequence motif), Chonluten's (EDG) specific DNA binding sequences, affinities, and genome-wide patterns have NOT been characterized by high-resolution structural biology — so the proposed mechanism remains a working hypothesis; (6) pharmacological challenges — how a 3-amino-acid peptide achieves sufficient DNA sequence specificity for bronchopulmonary tissue selectivity, actual binding affinity unmeasured, in vivo bioavailability and lung tissue penetration not fully characterized, plasma stability with potential aminopeptidase degradation of N-terminal glutamic acid, and nuclear entry to compacted heterochromatin are not fully resolved; (7) theoretical safety concerns — because Chonluten is proposed to stimulate epithelial cell proliferation and modulate gene expression and DNA methylation, there is a theoretical concern that it could promote the growth of lung cancers (such as bronchogenic carcinoma, adenocarcinoma, squamous cell carcinoma) or other cancers — this has NOT been demonstrated, and no long-term carcinogenicity studies have been conducted, but it is a biologically plausible concern given the cell proliferation and gene regulation mechanisms, and individuals with active cancer or a history of lung cancer should exercise extreme caution and consult an oncologist before use; (8) unknown long-term safety — the long-term safety of Chonluten in humans has not been established; (9) product quality variability — as a research chemical sold by numerous online vendors, the quality, purity, potency, and accuracy of labeling of Chonluten can vary dramatically between vendors, with potential for under-dosing, contamination, mislabeling, or counterfeit products; and (10) no established optimal dosing — the optimal dose, route of administration, frequency, and duration of Chonluten treatment have not been established through formal clinical trials, and vendor-recommended dosing is based on extrapolation from in vitro studies, animal data, and general Khavinson peptide dosing patterns, rather than on human dose-finding studies. In summary, Chonluten represents a theoretically interesting and mechanistically novel approach to respiratory epithelial regulation and lung health — based on the Khavinson theory of short peptide epigenetic gene regulation, with promising in vitro findings suggesting anti-inflammatory (TNF-α, IL-6, COX-2), antioxidant (SOD, catalase), and epithelial repair effects, and clinical observations from Russian centers suggesting potential benefits in COPD, chronic bronchitis, post-TB rehabilitation, and age-related lung decline — but it remains an experimental/investigational compound with a very limited evidence base (no RCTs, no independent Western validation, sparse old Russian-language literature, and even a negative finding in Khavinson's own research), and its efficacy and safety in humans are unknown. Individuals with respiratory conditions should consult a qualified pulmonologist or healthcare provider to discuss evidence-based, FDA-approved treatment options — including smoking cessation (the single most important intervention for COPD/chronic bronchitis), inhaled bronchodilators (beta-agonists, anticholinergics), inhaled corticosteroids (for eosinophilic COPD/asthma), pulmonary rehabilitation, oxygen therapy (for hypoxemia), vaccinations (influenza, pneumococcal, COVID-19), and in advanced cases, surgical options (lung volume reduction surgery, lung transplantation) — rather than relying on unproven research peptides. The product offered here is injectable Chonluten T-34 (20mg vial), intended for in-vitro laboratory research use only — it is not for human or veterinary use^{[1][2][3][4][5][6][7][8][9][10][11][12]}.

References

1. PeptideInsight Research. Chonluten — anti-inflammatory, COX-2, TNF-α. PeptideInsight.com. 2026. (COX-2 inhibition: Chonluten regulates expression of cyclooxygenase-2, inducible enzyme responsible for prostaglandin synthesis during inflammation; TNF-alpha suppression: in THP-1 monocyte/macrophage cell line, Chonluten inhibited tumor necrosis factor [TNF] production by monocytes exposed to bacterial lipopolysaccharide [LPS], model of acute inflammatory stimulation; anti-inflammatory effects complement Chonluten's antioxidant...; Oral administration of Chonluten [EDG] combined with Bronchogen [AEDL] reported effective for bronchopulmonary pathology including COPD + chronic bronchitis with asthmatic component; EDG tripeptide enhanced effectiveness of standard therapy in patients with chronic bronchitis; clinical observations from Russian studies, NOT validated through RCTs)
2. Peptide Dosage Research. Chonluten Dosage Chart, Schedule & Reconstitution Protocol — target genes, animal models, gerontology. PeptideDosage.org. 2026. (For Chonluten, target genes reported to include stress-response genes [c-Fos, heat shock protein 70], antioxidant enzymes [superoxide dismutase, catalase], inflammatory mediators [cyclooxygenase-2, tumor necrosis factor-alpha], differentiation/proliferation markers in bronchial epithelium; broader pharmacological narrative emphasizes restoration of bronchial epithelial function in age-related + inflammatory respiratory disease; reported preclinical effects include increased...; Animal models of COPD report Chonluten administration reduces inflammatory infiltrate, normalizes alveolar architecture, improves indices of respiratory mechanics relative to untreated controls, supporting inclusion in Russian-language respiratory rehabilitation protocols; Gerontological studies in aged rodents document age-associated declines in bronchial ciliated cell density, mucociliary clearance, antioxidant enzyme activity partially reversed by cyclic Chonluten administration, supporting bioregulator hypothesis)
3. Kalios Health Research. Chonluten Preclinical — mucociliary, anti-inflammatory, antioxidant. Kalios.health. 2026. (Mucociliary function: proposed modulation of mucin-gene [MUC5AC] expression + ciliated-cell-associated structural genes, described in bronchial epithelial models; Anti-inflammatory/cytokine modulation: reductions in TNF-α [major inflammatory signaling molecule], IL-6 [pro-inflammatory cytokine tied to chronic inflammation], IL-1β expression described in stressed mucosal-epithelium cultures exposed to EDG; Antioxidant defense: upregulation of SOD,...)
4. StackBuilder Research. Chonluten — mechanism, effects. StackBuilder.com. 2026. (Chonluten acts as peptide bioregulator that penetrates cell nuclei + interacts directly with DNA promoter regions, specifically upregulating gene expression in bronchial + alveolar epithelial cells to restore normal protein synthesis patterns disrupted by aging or disease; promotes differentiation + proliferation of bronchial mucosa cells, enhances mucociliary clearance, supports surfactant production by type II pneumocytes; exhibits immunomodulatory properties by normalizing cytokine profiles in lung tissue + reducing pathological inflammatory signaling)
5. Peptide List Research. Chonluten — sequence, origin, classification. PeptideList.org. 2026. (Chonluten = synthetic tripeptide consisting of glutamic acid, aspartic acid, glycine [Glu-Asp-Gly], developed as part of Vladimir Khavinson's bioregulator peptide system at St. Petersburg Institute of Bioregulation and Gerontology; classified as Cytogen — lab-synthesized short peptide designed to mirror regulatory effects of peptides naturally found in bronchial + lung tissue; principal biological target = respiratory...)
6. Peptide Initiative Research. Chonluten — T-34, EDG, bronchopulmonary. PeptideInitiative.com. 2026. (Chonluten = synthetic tripeptide [Glu-Asp-Gly or EDG] classified as T-34 in Khavinson's bioregulator system, specifically designed to target bronchopulmonary system — lungs + bronchial tree; developed by Prof. Vladimir Khavinson as part of systematic research program identifying organ-specific ultrashort peptides; Chonluten restores respiratory epithelial function through direct DNA interaction at bronchopulmonary gene promoters, normal...)
7. Cenexa Labs Research. Chonluten Peptide Research – Complete Guide — T-34, EDG, nuclear penetration. CenexaLabs.com. 2026. (Chonluten, also called T-34 tripeptide or EDG peptide, is three-amino-acid compound originally isolated from bronchial epithelial tissue, studied for unusual ability to penetrate cell nuclei + interact directly with DNA regulatory regions; unlike most research peptides working through surface receptors, Chonluten tripeptide research focuses on direct gene regulation in respiratory + gastrointestinal tissues, with additional investigation into inflammatory pathway modulation + cellular aging; all research on Chon...)
8. Jay Campbell Research. Chonluten Peptide: Uses, Benefits, Side Effects and Dosage — DNA methylation, STAT1/STAT3. JayCampbell.com. 2025. (Chonluten's tiny molecular size allows it to penetrate cells + go straight to nucleus; once inside, binds to DNA + histone proteins; then interacts with actual genes controlling inflammation, tissue repair, cellular survival; regulates DNA methylation, flipping switches determining which genes get turned on or off [ex., activating STAT1 to support healthy immune signaling while dialing down STAT3, linked to aggressive inflammation])
9. Peptadex Research. Chonluten — clinical applications, chronic bronchitis, post-TB, senile pulmonary involution. Peptadex.com. 2026. (Chronic bronchitis in smokers + occupationally exposed workers: clinical series from St. Petersburg pulmonology centers described reductions in cough frequency, sputum volume, exacerbation rate when Chonluten courses added to standard care; Post-tuberculosis rehabilitation: in Russian TB clinical tradition, Chonluten studied as part of multi-peptide protocols during recovery phase, with reported improvements in spirometry + exercise tolerance; Senile pulmonary involution...)
10. CertaPeptides Research. Bioregulator Peptides: Complete Guide to Khavinson Peptides and Organ-Specific Research — Chonluten table. CertaPeptides.com. 2026. (Table: Bioregulator = Chonluten; Sequence = Gly-Glu-Pro [note: some sources say GEP, most say EDG — discrepancy in literature]; Length = 3 AA; Organ/system target = Lungs/Bronchial; Main research area = epithelial cell regeneration, surfactant; Principal study reference = Khavinson et al. [2006]; together with increased expression of surfactant protein genes, authors proposed Chonluten as candidate for investigation of lung tissue regeneration, although no in vivo data presented in that specific publication)
11. Khavinson V. (Prof.) Morphofunctional Fundamentals for Peptide Regulation of Aging. Khavinson.info / PDF. (NEGATIVE FINDING: "However, the T–34 peptide of the respiratory system was ineffective." The obtained results confirmed previously obtained data about tissue specific manner of peptide mediated effects, occurring not only at tissue/organ levels but also at cellular level; study revealed geroprotector effects of peptides based on capacity to activate intracellular processes, most significant = protein synthesis; T-34 [Chonluten] = one of peptides tested, found ineffective in this particular geroprotective assay — important negative finding must be disclosed)
12. PeptideInfo Wiki / Int J Mol Sci 2022. Chonluten — THP-1 monocyte study, Khavinson co-author. PeptideInfo.wiki. 2026. (Int J Mol Sci 2022, with Khavinson as co-author: Chonluten — among several Khavinson peptides — reduced TNF + IL-6 stimulated by LPS in human THP-1 monocytes/macrophages + altered proliferation/apoptosis + production of extracellular vesicles; Russian clinical claims [COPD, bronchitis...] NOT validated through RCTs; PepHealth Brazil: Chonluten [Bronchogen] = short peptide from Russian Khavinson school, proposed as "bioregulator" of bronchi; NOT approved [no ANVISA/FDA/EMA], no robust RCT, mechanism in humans not established; literature scarce, old, mostly Russian — this fact sheet separates what exists from what doesn't exist)
13. PeptideInsight Research. Bronchogen — biophysical DNA binding studies (AEDL, related peptide). PeptideInsight.com. 2026. (RELATED PEPTIDE COMPARISON: Bronchogen [AEDL, 4 aa] — biophysical studies using spectrophotometry, viscometry, circular dichroism demonstrated AEDL peptide interacts with DNA in major groove at guanine N7 site without visible distortion of double helix structure; peptide binds specifically to CTCC DNA sequence motif; these findings suggest mechanism distinct from conventional receptor-mediated signaling, AEDL directly accesses chromatin to modulate gene transcription; IMPORTANT: these biophysical DNA-binding data exist for Bronchogen [AEDL] but NOT for Chonluten [EDG] — Chonluten's specific DNA binding sequences/affinities/genome-wide patterns NOT characterized by high-resolution structural biology)